

Supplementary Table 3. Comparison of baseline characteristics between patients with and without the development of major adverse cardiovascular events (MACE)

Characteristics	Without MACE (n=4,082)	With MACE (n=42)	P-value
Treatment			
TAF, n (%)	933 (22.9)	5 (11.9)	0.134
TDF, n (%)	3,149 (77.1)	37 (88.1)	
Demographic characteristics			
Age (yr)	50.5 (41.9–57.7)	55.2 (48.9–60.9)	<0.001
Male, n (%)	2,471 (60.5)	30 (71.4)	0.137
Height, cm	166.6 (159.7–172.6)	166.0 (159.5–170.3)	0.497
Weight (kg)	66.0 (57.5–74.5)	67.4 (62.1–74.0)	0.440
Body mass index (kg/m ²)	23.9 (21.9–26.1)	24.4 (22.9–26.9)	0.215
Systolic BP (mmHg)	122.0 (109.0–134.0)	132.0 (119.0–140.0)	0.018
Diastolic BP (mmHg)	73.0 (65.0–80.0)	76.0 (67.0–84.0)	0.289
Smoking status, n (%)			0.040
Never smoker	1,891 (46.3)	20 (47.6)	
Current smoker	733 (18.0)	12 (28.6)	
Past smoker	605 (14.8)	8 (19.0)	
Not available	853 (20.9)	2 (4.8)	
Comorbidities			
Diabetes, n (%)	369 (9.0)	13 (31.0)	<0.001
Hypertension, n (%)	593 (14.5)	20 (47.6)	<0.001
Stroke, n (%)	23 (0.6)	1 (2.4)	0.602
Myocardial infarction, n (%)	8 (0.2)	1 (2.4)	0.175
Heart failure, n (%)	19 (0.5)	0 (0.0)	0.999
Coronary artery disease, n (%)	40 (1.0)	20 (47.6)	<0.001
Cirrhosis, n (%)	1,656 (40.6)	19 (45.2)	0.649
Fatty liver, n (%)	631 (15.5)	6 (14.3)	0.385
HCC, n (%)	276 (6.8)	5 (11.9)	0.313
Laboratory findings			
Platelets (×10 ³ /μL)	167.0 (120.0–211.0)	168.0 (110.5–216.0)	0.940
AST (IU/L)	56.0 (35.0–93.0)	55.0 (37.0–97.5)	0.819
ALT (IU/L)	57.0 (30.0–122.0)	49.5 (36.0–101.0)	0.845
Prothrombin time, INR	1.1 (1.0–1.2)	1.1 (1.0–1.2)	0.201
Albumin (g/dL)	3.9 (3.5–4.1)	3.5 (3.0–4.0)	0.011
Total bilirubin (mg/dL)	0.8 (0.6–1.1)	0.8 (0.6–1.3)	0.478
Creatinine (mg/dL)	0.8 (0.7–0.9)	0.8 (0.7–1.0)	0.140
eGFR (mL/min/1.73m ²)	101.0 (93.0–109.5)	96.0 (81.0–103.0)	0.001
Total cholesterol (mg/dL)	169.0 (144.0–194.0)	153.0 (124.0–182.0)	0.009
HDL (mg/dL)	51.0 (41.0–61.0)	41.0 (34.0–51.0)	0.007
LDL (mg/dL)	108.0 (84.0–132.0)	96.0 (75.0–109.0)	0.073
Triglyceride (mg/dL)	87.0 (68.0–116.5)	100.0 (71.0–181.0)	0.041
HBeAg-positive, n (%)	1,729 (47.5)	13 (36.1)	0.232

Supplementary Table 3. Continued

Characteristics	Without MACE (n=4,082)	With MACE (n=42)	P-value
HBV DNA (log ₁₀ IU/mL)	5.5 (3.3–7.1)	4.8 (3.2–6.1)	0.167
Medication use at baseline			
Aspirin, n (%)	97 (2.4)	11 (26.2)	<0.001
Clopidogrel, n (%)	46 (1.1)	7 (16.7)	<0.001
Lipid-lowering agent, n (%)	318 (7.8)	11 (26.2)	<0.001

Data are presented as a frequency and proportion or as a mean value with interquartile range.

TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; BP, blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.